May 2014

Life sciences

 

Quebec International partners with BioWin to offer a training program specifically geared towards life science entrepreneurs

Quebec International is pleased to announce that it has reached an agreement in principle with BioWin, the healthcare competitiveness cluster based in Wallonia, Belgium. The agreement covers licensing rights under BioWin’s BioPharE program. For BioWin, this is the first time that rights have been licensed under this high-level program. As part of its role in the partnership, the Continuing Education Department at Sainte-Foy CEGEP will administer training activities during the implementation of the program, which is specifically geared towards life science entrepreneurs. 

 

Aeterna Zentaris Appoints Dr. Richard Sachse as Chief Scientific Officer

Aeterna Zentaris announced the appointment of Richard Sachse, MD, PhD, as Senior Vice President, Chief Scientific Officer. Before joining Aeterna Zentaris, Dr. Sachse was Vice President, Head of Global Translational Medicine at Boehringer Ingelheim.

 

Université Laval and Roche team up to test promising compounds for several disorders of the brain, including autism spectrum disorders

Thanks to this joint initiative, Université Laval researcher Yves De Koninck and his team will be able to pursue the development of the many scientific discoveries and advances they have made in the last 10 years. Dr. De Koninck is a Professor in Université Laval’s Faculty of Medicine, Scientific Director of the Institut Universitaire en Santé Mentale de Québec, and an internationally renowned expert in the fields of neurology and neurophotonics.

 

Aeterna Zentaris Announces Closing of US$13.2 Million Public Offering of Common Shares and Warrants

Aeterna Zentaris announces the closing of its previously announced public offering of 11.0 million units generating net proceeds of approximately US$12.2 million, with each unit consisting of one common share and 0.8 of a warrant to purchase one common share, at a purchase price of US$1.20 per unit. Each warrant is exercisable for a period of five years at an exercise price of US$1.25 per share. Canaccord Genuity Inc. acted as the sole book-running manager, and Maxim Group LLC, H. C. Wainwright & Co., LLC and MLV & Co LLC acted as co-managers for the Offering.

 

Atrium Innovations Inc. Receives Final Court Approval of Arrangement with the Permira Funds

Atrium Innovations announces that the Superior Court of Québec issued a final order approving the previously announced plan of arrangement providing for the acquisition of all of the outstanding common shares of Atrium for cash consideration of $24.00 per common share by corporations backed by the Permira funds and the acquisition by the Corporation of all of its outstanding convertible debentures.

 

Government of Canada Celebrates New Business-Led Research Network in Québec City

The Honourable Greg Rickford, Minister of State (Science and Technology), was in Québec City today to celebrate the new Business-Led Network of Centres of Excellence in Precision Therapeutics (PreThera Research). As a result of the 2014 Business-Led Networks of Centres of Excellence (BL-NCE) competition, PreThera Research was awarded $15 million. This support will enable the Network's researchers to apply their knowledge of biomarkers

 

TSO3 granted European patent - Japanese and Australian patents approved

TSO3 announces that the Company has been notified by the European Patent Office of its decision to grant a patent applied for in 2010. This patent describes a method for controlling condensation of hydrogen peroxide (H2O2) when sterilizing medical devices with hydrogen peroxide, either used alone or in combination with ozone or other chemistries. Several other patent applications covering TSO3's technology are still pending in the United States, Europe,Japan and elsewhere in the world.  The Company has also been notified by the Japanese and Australian Patent Offices of their intent to grant two of these other patents.

 

Scientists identify protein linked to most common movement disorder

A team of researchers from Université Laval and CHU de Québec identified unusually high levels of a certain protein in the brains of people suffering from essential tremor (ET), a movement disorder that affects 4% of the adult population. The discovery, the details of which were published in the most recent edition of the journal Movement Disorders, could lead to an effective treatment for this neurological condition, which is 10 times more prevalent than Parkinson’s disease.

 

Merck Canada announces $2-million grant to support personalized treatment in cancer

At the 6th Annual National Conference to Defeat Cancer, organized by Coalition Priorité Cancer, Merck Canada reinforced the company's continued commitment to the Quebec life sciences research innovation sector by announcing a $2-million grant to the Quebec - Consortium de recherche en oncologie clinique (Q-CROC).

 

Aeterna Zentaris: Poster Presentation at AACR Meeting Provides Rationale for New Therapeutic Opportunities in Oncology with Erk Inhibitors

Aeterna Zentaris announces that a poster on AEZS-134, a highly potent and selective ATP competitive Erk inhibitor, provides rationale for new therapeutic opportunities in oncology with this compound. The poster, titled, "Erk Inhibition as a Therapeutic Option for the Treatment of Raf- and Mek- Inhibitor Resistant Tumors", I. Seipelt, P. Schmidt, H. Märzhäuser, M. Gerlach, K. Jung, T. Schuster and M. Teifel, was presented yesterday by Irene Seipelt, Ph. D., Director, Preclinical Development at Aeterna Zentaris, during a poster session at the American Association for Cancer Research Annual Meeting in San Diego, California.

 

Opsens grants Abiomed US$6 million license for circulatory assist device

Opsens is pleased to announce it has entered into an Amended and Restated Co-Development Agreement  with Abiomed, in connection with its miniature optical pressure sensor technology for applications in circulatory assist devices, such Agreement replacing the Co-Development Agreement initially entered into in January 2010.